Jan 20 (Reuters) - Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have ...
Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.
Zacks Investment Research on MSN
NVO expands Aspect tie-up to advance curative diabetes cell therapies
Novo Nordisk NVO and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback